MA44699A - Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer - Google Patents

Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer

Info

Publication number
MA44699A
MA44699A MA044699A MA44699A MA44699A MA 44699 A MA44699 A MA 44699A MA 044699 A MA044699 A MA 044699A MA 44699 A MA44699 A MA 44699A MA 44699 A MA44699 A MA 44699A
Authority
MA
Morocco
Prior art keywords
antagonist
oligonucleotide
cancer
treatment
combination
Prior art date
Application number
MA044699A
Other languages
English (en)
Inventor
Robert L Coffman
Andrew Evan Denker
Cristiana Guiducci
Robert S Janssen
Robert A Kastelein
David Ross Kaufman
Uyen Truong Phan
Svetlana Sadekova
Ying Yu
Original Assignee
Merck Sharp & Dohme
Surefire Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Surefire Medical Inc filed Critical Merck Sharp & Dohme
Publication of MA44699A publication Critical patent/MA44699A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA044699A 2015-05-29 2016-05-26 Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer MA44699A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562169309P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
MA44699A true MA44699A (fr) 2021-05-05

Family

ID=57441888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044699A MA44699A (fr) 2015-05-29 2016-05-26 Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer

Country Status (13)

Country Link
US (2) US10751412B2 (fr)
EP (2) EP3302501B1 (fr)
JP (2) JP6893608B2 (fr)
KR (1) KR20180014009A (fr)
CN (1) CN108025018B (fr)
AU (1) AU2016271018A1 (fr)
BR (1) BR112017025562A2 (fr)
CA (1) CA2986126A1 (fr)
ES (1) ES2985394T3 (fr)
MA (1) MA44699A (fr)
MX (1) MX2017015308A (fr)
RU (1) RU2017145558A (fr)
WO (1) WO2016196173A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
DK2972193T3 (da) 2013-03-13 2020-03-23 Univ Miami Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
US20160101128A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LT3240801T (lt) * 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
WO2018039629A2 (fr) 2016-08-25 2018-03-01 Northwestern University Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
WO2018201028A1 (fr) 2017-04-28 2018-11-01 Merck Sharp & Dohme Corp. Biomarqueurs pour thérapies anticancéreuses
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
KR20200068655A (ko) 2017-10-13 2020-06-15 머크 샤프 앤드 돔 코포레이션 미만성 거대 b 세포 림프종의 치료를 위한 조성물 및 방법
WO2019084418A1 (fr) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. Compositions et méthodes pour le traitement du cancer du foie
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
WO2019200238A1 (fr) * 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinaisons comprenant un oligonucléotide de type cpg-c et un inhibiteur d'histone désacétylase pour le traitement du cancer
WO2020081398A1 (fr) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combinaison comprenant un oligonucléotide de type cpg-c et un antagoniste de pd-1 pour le traitement du cancer du sein
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) * 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
WO2020119728A1 (fr) * 2018-12-12 2020-06-18 尚华科创投资管理（江苏）有限公司 Anticorps monoclonal anti-interleukine 5(il-5) humaine et son utilisation
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
EP3845649B1 (fr) * 2019-12-31 2025-09-24 Industrial Technology Research Institute Complexe acide nucléique-médicament et utilisation de cela
CN114981436A (zh) * 2020-01-10 2022-08-30 Sbi生物技术有限公司 新tlr9激动剂
CA3189834A1 (fr) * 2020-07-24 2022-01-27 Ronald Levy Vaccin a trois constituants contre la covid-19
EP4217064A4 (fr) * 2020-09-22 2024-08-07 TriSalus Life Sciences, Inc. Thérapie anticancéreuse faisant intervenir des agonistes de récepteurs de type toll
JP2023542989A (ja) * 2020-09-22 2023-10-12 トリサルース・ライフ・サイエンシズ・インコーポレイテッド トール様受容体アゴニストを使用したがん治療
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
WO2022110010A1 (fr) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 Utilisation d'un activateur immunitaire, d'un antigène et d'un anticorps dans la préparation d'un produit pour la prévention et le traitement de tumeurs
KR20240004419A (ko) * 2021-04-01 2024-01-11 트라이살루스 라이프 사이언시즈, 인크. 톨-유사 수용체 작용제를 사용한 암 요법
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
WO2025233224A1 (fr) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'atr en combinaison avec une thérapie anti-pd(l)1

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
CA2244946C (fr) 1996-01-30 2010-04-13 The Regents Of The University Of California Vecteurs d'expression genique generant une reponse immune specifique d'un antigene et leurs procedes d'utilisation
EP0930893B1 (fr) 1996-10-11 2005-04-13 The Regents of The University of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
EP1009413B1 (fr) 1997-09-05 2007-02-14 The Regents Of The University Of California Utilisation d'oligonucleotides immunostimulants pour la prevention ou le traitment de l'asthme
CA2352572C (fr) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Anticorps anti-interferon gamma humanises
EP1176966B1 (fr) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2381309T3 (es) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2328920A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2738700T3 (es) * 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
WO2012006634A2 (fr) * 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Thérapie peptidique par antigène prostatique spécifique (psa)
CA2830806C (fr) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Formulations stables d'anticorps diriges contre le recepteur humain pd-1 de la mort programmee et traitements associes
EA026924B1 (ru) * 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
RU2689760C2 (ru) * 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2981821B2 (fr) * 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Test immunohistochimique pour détecter l'expression du ligand de mort programmée 1 (pd-l1) dans un tissu tumoral
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
JP2016534044A (ja) * 2013-10-11 2016-11-04 ジェネンテック， インコーポレイテッド 癌の免疫療法のためのｃｂｐ／ｅｐ３００ブロモドメインインヒビターの使用
EP3136858A4 (fr) 2014-05-02 2018-01-03 Nitor Therapeutics Guanosine comme potentialisatrice du système immunitaire à médiation par les récepteurs toll
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
US20180161427A1 (en) 2015-05-29 2018-06-14 Merck Sharp & Dohme Corp. Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer

Also Published As

Publication number Publication date
CN108025018B (zh) 2021-08-17
US20210196819A1 (en) 2021-07-01
BR112017025562A2 (pt) 2018-08-07
RU2017145558A (ru) 2019-07-01
JP2021102627A (ja) 2021-07-15
JP2018516911A (ja) 2018-06-28
CA2986126A1 (fr) 2016-12-08
EP3892284B1 (fr) 2024-05-22
US11918648B2 (en) 2024-03-05
US20180169229A1 (en) 2018-06-21
AU2016271018A1 (en) 2017-11-30
HK1252652A1 (zh) 2019-05-31
JP6893608B2 (ja) 2021-06-23
CN108025018A (zh) 2018-05-11
KR20180014009A (ko) 2018-02-07
WO2016196173A1 (fr) 2016-12-08
MX2017015308A (es) 2018-07-06
JP7236483B2 (ja) 2023-03-09
EP3302501A1 (fr) 2018-04-11
EP3892284A1 (fr) 2021-10-13
ES2985394T3 (es) 2024-11-05
EP3302501B1 (fr) 2021-09-22
EP3302501A4 (fr) 2019-02-27
US10751412B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
EP3481393A4 (fr) Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3302554A4 (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer